Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study

Fig. 1

Overview of qualitative interview study and quantitative online survey design. *Notable exclusion criteria included individuals with SMA who were enrolled in a clinical trial or currently being or having previously been treated with risdiplam (EVRYSDI™) or onasemnogene abeparvovec-xioi (ZOLGENSMA®) treatment. However, individuals who were in the maintenance dosing phase of nusinersen (SPINRAZA®) treatment were considered eligible as it was considered to be a sufficient time on treatment for an individual to understand their changes in function and would not influence their perspective of how the patient-friendly MFM32 items relate to ADLs. Individuals who had received nusinersen treatment but discontinued were also included within the quantitative online survey sample. ADL, activities of daily living; MFM32, 32-item motor function measure

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us